← Leaderboards
Milton L Greenberg
Vivreon Biosciences, Llc
$19,702,937
Attributed
$19,702,937
Total exposure
16
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.1M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,702,937 · 16
By mechanism
R44$15,129,522 · 6
R43$2,577,030 · 9
SB1$1,996,385 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBiological SciencesFundingPharmaceutical PreparationsSmall MoleculeSmall Business Innovation Research GrantOralPropertyMissionProgramsTherapeutic CandidateInflammatoryChronicLeadInvestigational DrugsToxicologyDosePre-ClinicalInnovationPersonsRegimenSignal TransductionPreventGrant
Grant awards (30)
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$1,996,385
SB1 · FY2025 · AG · contact PI
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder$1,097,854
R44 · FY2025 · DA · contact PI
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis$999,997
R44 · FY2025 · AI · contact PI
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder$1,401,740
R44 · FY2024 · DA · contact PI
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis$999,997
R44 · FY2024 · AI · contact PI
IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy$502,010
R44 · FY2024 · CA · contact PI
Development of a Novel Calcium Channel Therapeutic for Dystrophinopathies$306,872
R43 · FY2024 · AR · contact PI
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$1,223,378
R44 · FY2023 · AG · contact PI
Development of a Novel Calcium Channel Therapeutic for the Treatment of Asthma$352,030
R43 · FY2023 · HL · contact PI
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder$319,991
R44 · FY2023 · DA · contact PI
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$50,000
R44 · FY2023 · AG · contact PI
IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy$1,371,030
R44 · FY2022 · CA · contact PI
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$1,276,596
R44 · FY2022 · AG · contact PI
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis$299,989
R43 · FY2022 · AI · contact PI
Development of a Novel CRAC Channel Therapeutic for the Treatment of Primary Hyperhidrosis$245,256
R43 · FY2022 · AR · contact PI
Predevelopment of VV8321, a Novel CRAC Channel Therapeutic for the Treatment of Osteoarthritis$252,039
R43 · FY2021 · AR · contact PI
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$193,392
R44 · FY2021 · AG · contact PI
Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder$55,000
R43 · FY2021 · DA · contact PI
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$1,249,999
R44 · FY2020 · AG · contact PI
Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder$349,967
R43 · FY2020 · DA · contact PI
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy$249,806
R44 · FY2020 · CA · contact PI
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy$224,700
R44 · FY2020 · CA · contact PI
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$1,250,000
R44 · FY2019 · AG · contact PI
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy$1,004,278
R44 · FY2019 · CA · contact PI
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$270,902
R43 · FY2019 · AG · contact PI
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$745,976
R44 · FY2018 · AG · contact PI
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy$225,000
R43 · FY2018 · CA · contact PI
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$746,325
R44 · FY2017 · AG · contact PI
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, for the Treatment of Ulcerative Colitis$219,975
R43 · FY2017 · AI · contact PI
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$222,453
R44 · FY2016 · AG · contact PI